Athersys Sees Efficacy Sign In MultiStem Phase I Safety Study In Heart Attack
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Heart attack patients treated with Athersys' adult stem cell product MultiStem during a Phase I safety study showed improvement in cardiac function, a surprise early efficacy signal that has the company headed into Phase II studies with a spring in its step
You may also be interested in...
Stem Cell Therapies Walk A Risky Regulatory Road
As the most advanced stem cell therapies, known collectively these days as "regenerative medicine," edge into the clinic, much about the field remains unresolved – including basic regulatory questions and whether the therapies, which hope to restore circulation to ischemic tissue or function to damaged nerves, for example, will even work in humans.
Pfizer Licenses Athersys' Stem Cell Technology For IBD Drug Development
Following the deal news, Athersys' stock price soared during same-day trading.
FDA Priority Review Voucher Redemption Fee Set At $4.6 Million In FY 2011
Redeeming a priority review voucher obtained by developing a drug for a tropical disease will cost companies $6.1 million in fiscal 2011